SCHEMBL19137960

SCHEMBL19137960

CN1CCN(c2ccc(-c3nc4ccncc4[nH]3)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.60
▸ SOAT1 P35610 1/20 0.60
▸ KCNH2 Q12809 1/20 0.60
▸ ALDH1A1 P00352 6/20 0.59
▸ SMN1; SMN2 Q16637 5/20 0.59
▸ TOP1 P11387 3/20 0.59
▸ TOP2A P11388 3/20 0.59
▸ HPGD P15428 2/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ KDM4E B2RXH2 3/20 0.57
▸ PKM P14618 2/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ AURKA O14965 1/20 0.56
▸ MEN1 O00255 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ SLCO2B1 O94956 1/20 0.54
▸ GLA P06280 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19175780 0.88 ALDH1A1 (0.61) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137937 0.87 ALDH1A1 (0.59) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL3510801 0.83 ACHE (0.74) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL14665656 0.81 ALDH1A1 (0.79) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL21017604 0.80 DGAT1 (0.63) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137927 0.79 DGAT1 (0.71) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL14115831 0.78 ALDH1A1 (0.70) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137926 0.77 AURKA (0.56) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL24075398 0.77 DGAT1 (0.66) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL31473450 0.77 TNKS (0.54) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017132511-A1 BENZIMIDAZOLE COMPOUNDS, USE AS INHIBITORS OF WNT SIGNALING PATHWAY IN CANCERS, AND METHODS FOR PREPARATION THEREOF SOUTHERN RESEARCH INSTITUTE (US) 2017-08-03 — — WO disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof WNT1, WNT3, CTNNB1 DGAT1 2252/4885SOAT1 2222/4885KCNH2 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback